Results 211 to 220 of about 3,635,661 (309)

Growing Diversity in Data Science: Shared Lessons from Clinical Trials [PDF]

, 2019
Simari, Robert D.
core   +2 more sources

Cis‐regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation

Molecular Oncology, EarlyView.
The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués, Aracele Martinez‐Mendez, John Crown, Alex Eustace   +3 more
wiley   +1 more source

Adaptive Biomarker-Based Design for Early Phase Clinical Trials. [PDF]

Stat Med
Serra A, Saint-Hilary G, Guilleminot S, Geronimi J, Mozgunov P.   +4 more
europepmc   +1 more source

Ethical and methodological considerations on conducting clinical research in poor and low-income countries: Viewpoint of the authors of the BEST TRIP ICP randomized trial in Latin America

, 2015
Randall M. Chesnut, Nancy Temkin, Sureyya Dikmen, Carlos Rondina, Walter Videtta, Silvia Lujan, Gustavo Petroni, James Pridgeon, Jason Barber, Joan Machamer, Kelley Chaddock, JuanitaM Celix, Marianna Cherner, Terence Hendrix   +13 more
openalex   +1 more source

European Code Against Cancer, 5th edition – hormone replacement therapy, other common medical therapies and cancer

Molecular Oncology, EarlyView.
The 5th edition of the European Code Against Cancer (ECAC5) contains 14 recommendations on cancer prevention. Here, we update the cancer prevention recommendations regarding the use of hormone replacement therapy (HRT), which is positioned as recommendation number 13 of the ECAC5.
Mangesh A. Thorat, Marc Arbyn, David Baldwin, Xavier Castells, Solveig Hofvind, Urska Ivanus, Carlo Senore, Esther Toes‐Zoutendijk, Carlijn van der Aalst, Carlos Canelo‐Aybar, Fiorella Karina Fernández‐Sáenz, Ariadna Feliu, Hajo Zeeb, Andre L. Carvalho, Erica D'Souza, David Ritchie, Carolina Espina, Iris Lansdorp‐Vogelaar, Andrea DeCensi   +18 more
wiley   +1 more source

Use of microbiome analysis as a complementary endpoint in clinical trials. [PDF]

iScience
Velo-Suarez L, Guilloux CA, Le Berre R, Gouriou S, Rault G, Mottier D, Meijer L, Héry-Arnaud G.   +7 more
europepmc   +1 more source

Clinical Trial Highlights: Anti-Inflammatory and Immunomodulatory Agents

Bina Patel, Julia C. Greenland, Caroline H. Williams‐Gray   +2 more
openalex   +1 more source

PL-010 Turmeric enema: a novel therapy for C. difficile colitis (CDAD): A randomized, double blinded, placebo controlled prospective clinical trial

, 2011
Purba Basu, Nitya Krishnaswamy, N.J. Shah, Tanushree Nair, Sakina Farhat, Lynn Ang   +5 more
openalex   +1 more source

Clinical Trials [PDF]

, 2016
Nunn, Andrew J, Phillips, Patrick PJ
core  

Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies

Molecular Oncology, EarlyView.
We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck, Nele De Meulenaere, Thomas Vanpoucke, Joe Ibrahim, Dieter Peeters, Suresh Krishan Yogeswaran, Wen Wen, Paul Van Schil, Jeroen M. H. Hendriks, Jo Raskin, Jan van Meerbeeck, Guy Van Camp, Ken Op de Beeck   +12 more
wiley   +1 more source